RxDoctor Payments Data

Dimitrios Karmpaliotis, MD

Interventional Cardiology · Morristown, NJNPI 1033161138

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $95,007 of the $129,412 with a category attached, or 73.4%. 26 manufacturers reported payments, led by Boston Scientific at 48.9% of the total. Reporting peaked in 2019 at $60,907 and has fallen 99.2% since, to $494 in 2025. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$129,412in general payments, 2019–2025

Across 227 payments — averaging $570.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$63K
  • Abiomed$45K
  • Abbott$10K
  • Teleflex LLC$7K
  • Medtronic$2K
  • Actelion Pharmaceuticals US, Inc.$379
  • plus $1K from 20 others
$93,611in research payments, 2019–2025

Across 19 payments — averaging $4926.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Arrow International, Inc.$62K
  • Medtronic$17K
  • Philips North America LLC$15K
  • Abiomed$342

What the payments were for

  • Consulting fees$14,48811%
  • Speaking & faculty fees$95,00773%
  • Travel & lodging$11,6719%
  • Food & beverage$8,2466%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,412 in reported general payments places this provider in the 90th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$114,985
Medicare patients
169
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →